...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Clinical and Cost Implications of Treating Schizophrenia: Safety, Efficacy, Relapse Prevention, and Patient Outcomes
【24h】

Clinical and Cost Implications of Treating Schizophrenia: Safety, Efficacy, Relapse Prevention, and Patient Outcomes

机译：治疗精神分裂症的临床和费用含义：安全性，疗效，预防复发和患者结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Today, clinicians have an array of antipsychotic medications to choose from in treating patients with schizophrenia, as weii as a range of programs and services designed to improve cognition and real-world functioning. Yet, perhaps only a third of patients can successfully live in the community long-term and remain in remission. Treatment failure or a relapse after what appeared to be significant improvement in a patient's psychotic symptoms and functioning also affects families, employers, payers, policy makers, and huge swathes of the health care system. In brief, shortcomings in the treatment of schizophrenia have a significant impact on society as a whole, an impact that can be measured not only in terms of health and well-being but in dollars and cents. Studies evaluating the efficacy and cost-efficacy of antipsychotic medications and other forms of intervention are abundant, but it is uncertain how much of this valuable information reaches the average clinician and can then be applied in daily interactions with patients.This InfoPack aims to synthesize some of the important findings on new antipsychotics by explaining how to use the data from head-to-head comparisons and meta-analyses to evaluate different agents and choose the best one for the patient. It also reviews the evidence on cognitive remediation and antipsychotics in improving cognition and functional capacity. In particular, several short-term and long-term studies of the atypical antipsychotic lurasidone are discussed, including findings associated with cognition and improved functional capacity, the side effect profile, relapse prevention, and the cost savings that may be achieved by reducing the direct costs of care through an evidence-based selection of medication.
机译：如今，临床医生可以选择多种抗精神病药物来治疗精神分裂症患者，这是一系列旨在改善认知和现实生活功能的计划和服务。然而，也许只有三分之一的患者可以成功地长期生活在社区并保持缓解。治疗失败或患者精神病症状和功能明显好转后的复发也影响家庭，雇主，付款人，政策制定者和大量医疗保健系统。简而言之，精神分裂症的治疗缺陷对整个社会都有重大影响，这种影响不仅可以通过健康和福祉来衡量，还可以以美元和美分来衡量。有关抗精神病药物和其他形式干预措施的疗效和成本效益的评估研究很多，但尚不确定有多少有价值的信息可以到达普通临床医生，然后可用于与患者的日常互动中。通过解释如何使用头对头比较和荟萃分析中的数据评估新的抗精神病药物的重要发现，以评估不同的药物并为患者选择最佳药物。它还回顾了有关认知补救和抗精神病药改善认知和功能能力的证据。特别是，讨论了一些非典型抗精神病药物卢拉西酮的短期和长期研究，包括与认知和改善的功能能力有关的发现，副作用概况，预防复发以及通过减少直接使用可节省的成本通过循证选择药物的护理费用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号